AWM
ALNY icon

Able Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Able Wealth Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2
Closed -$383 – 109
2023
Q4 		$383 Buy
+2
New +$341 ﹤0.01% 563

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Able Wealth Management's ALNY Position: Q1 2024 in Review

Able Wealth Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2024, closing a stake of 2 shares — an estimated $383 sold.

Able Wealth Management first reported a position in ALNY in Q4 2023 and held it in 1 quarter. The position peaked at $383 in Q4 2023. 498 funds tracked by Wall St. Rank hold ALNY as of Q1 2024.

  • Able Wealth Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Able Wealth Management sold 2 Alnylam Pharmaceuticals shares in Q1 2024, an estimated $383.
  • Able Wealth Management first reported a position in Alnylam Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Able Wealth Management's Alnylam Pharmaceuticals position peaked at $383 in Q4 2023.
  • 498 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2024.

Based on Able Wealth Management's 13F filing for Q1 2024, filed 1 Nov 2024.